Tai Chi Is Not Equivalent to Pulmonary Rehabilitation

Goldstein, Roger

doi:10.1016/j.chest.2018.06.037

Cited by 3 publications

(4 citation statements)

References 6 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized, double-blind phase IIIb study (NCT03095456), 207 patients with moderate to very severe COPD and suboptimal PIFR (< 60 L/min) were randomized to receive revefenacin 175 µg once daily via a standard jet nebulizer or tiotropium once daily via HandiHaler ® for 28 days [ 17 , 21 ]. On day 29, revefenacin and tiotropium effectively improved trough FEV 1 and FVC from baseline, with improvements numerically favouring revefenacin over tiotropium; however, these differences did not reach statistical significance (FEV 1 : p = 0.481; FVC: p = 0.104).…”

Section: Scientific Summarymentioning

confidence: 99%

See 1 more Smart Citation

Revefenacin: First Global Approval

Heo

2018

Drugs

View full text Add to dashboard Cite

Revefenacin (YUPELRI™) inhalation solution, a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD). In November 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD. This article summarizes the milestones in the development of revefenacin leading to this first global approval.

show abstract

Section: Scientific Summarymentioning

confidence: 99%

“…In a prespecified subgroup analysis, revefenacin significantly ( p ≤ 0.0407) improved trough FEV 1 and FVC from baseline compared with tiotropium in patients with severe to very severe COPD (i.e. FEV 1 < 50% of predicted), which accounted for ≈ 80% of enrolled patients [ 17 , 21 ].…”

Section: Scientific Summarymentioning

confidence: 99%

Revefenacin: First Global Approval

Heo

2018

Drugs

View full text Add to dashboard Cite

show abstract

“…The In-Check DIAL (Clement Clerke International Ltd.) has been used widely in studies to measure PIFRr (4–6, 8, 9). It is portable and provides an adjustable dial to simulate different DPI resistances.…”

Section: Analytic Validationmentioning

confidence: 99%

“…These wide ranges reflect measurements with different DPI resistances in different COPD populations. Two randomized controlled trials demonstrated that patients with severe to very severe COPD and a suboptimal PIFRr against the Diskus had greater improvements in lung function with a bronchodilator delivered by nebulization compared with a DPI (8, 9).…”

Section: Clinical Validationmentioning

confidence: 99%